Physician profile
David B Yu
NPI 1144287806
$4,014.01
in general payments reported to CMS, 2019-2025
32 companies · $785 in 2025
The $785 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $101 · 2021: $65.95 · 2022: $286 · 2023: $896 · 2024: $1,676 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,356.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,108.20 | 2021-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $993.00 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Corium, LLC | $430.43 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $308.00 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $147.21 | 2023-2025 | Vpriv, Eohilia |
| Neos Therapeutics, Lp | $99.48 | 2019-2023 | Cotempla Xr-Odt |
| Sanofi Pasteur INC. | $91.70 | 2019-2025 | |
| Pfizer INC. | $91.16 | 2023-2025 | |
| Cranial Technologies, INC | $88.52 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $65.55 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $54.27 | 2023-2024 | Farxiga, Flumist Quadrivalent |
| Lilly USA, LLC | $51.42 | 2022-2025 | Jardiance |
| Tris Pharma INC | $44.46 | 2020 | |
| Idorsia Pharmaceuticals US INC | $40.91 | 2023 | Quviviq |
| Novo Nordisk INC | $35.42 | 2022-2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries Lp | $35.19 | 2024 | |
| Hologic Sales and Service, LLC | $32.88 | 2024 | Thinprep 2000 Processor, Aptima |
| Amgen INC. | $31.40 | 2019-2024 | Repatha, Otezla |
| Noven Therapeutics, LLC | $28.37 | 2024 | Xelstrym |
| Seqirus USA INC | $26.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $25.33 | 2024 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $24.70 | 2023 | |
| Phadia US INC. | $24.13 | 2024 | Immunocap |
| Abbott Laboratories | $21.88 | 2025 | Freestyle Libre 3 |
| Recor Medical INC | $21.78 | 2025 | Paradise Ultrasound Renal Denervation System |
| Organon LLC | $17.90 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $15.40 | 2024 | |
| Boston Scientific Corporation | $15.04 | 2024 | Watchman Flx |
| Nestle Healthcare Nutrition INC. | $12.93 | 2022 | |
| Eisai INC. | $11.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.25 | 2019 | |
| Endogastric Solutions, INC | $7.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.